Cosmo Pharmaceuticals has announced encouraging results for an experimental drug, clascoterone, which could become the first innovative treatment for male pattern baldness in nearly 30 years.
In advanced clinical trials involving around 1,500 men, the treatment demonstrated striking effectiveness. One trial reported a 539% improvement in hair growth compared with a placebo, while another recorded a 168% improvement.
The drug is applied topically to the scalp and works by inhibiting androgen receptors, thereby reducing the impact of male hormones that contribute to hair loss.
The company plans to complete its long-term safety study by spring 2026 before submitting the drug for regulatory approval.
